Teva nabs experimental Tourette drug in $700M Emalex buyout

A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business. 

By Jacob Bell • April 29, 2026

Chiesi to buy KalVista in $1.9B deal for rare disease drug

The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.

By Kristin Jensen • April 29, 2026

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech

Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multiple myeloma drug.

By BioPharma Dive staff • April 29, 2026

FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results

Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.

By Ben Fidler • April 28, 2026

Coultreon banks $125M to support testing of former Galapagos immune drug

Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases. 

By Delilah Alvarado • April 28, 2026

Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.

By Gwendolyn Wu • April 28, 2026

Oruka surges as long-acting psoriasis drug shows early promise

A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently. 

By Delilah Alvarado • April 27, 2026

Veradermics soars on positive data for baldness treatment

The results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medications.  

By Jonathan Gardner • April 27, 2026

Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics

Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.

By BioPharma Dive staff • Updated April 24, 2026

Revolution drug shows promise in early pancreatic cancer

The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.

By Jonathan Gardner • April 22, 2026

Merck adds to pharma’s AI push; Roche details MS drug results

Merck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending a yearslong alliance.

By BioPharma Dive staff • April 22, 2026

Tortugas debuts with $106M and brain drugs from Hansoh, Eisai

Led by former Sage Therapeutics executives Jeff Jonas and Al Robichaud, the company is starting out with a portfolio of neurological medicines in clinical testing. 

By Gwendolyn Wu • April 21, 2026

BioAge says early data suggest ‘best-in-class’ potential for inflammation drug

The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an inflammasome linked to a variety of health conditions. 

By Kristin Jensen • April 21, 2026

Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy. 

By Gwendolyn Wu • April 21, 2026

Trump executive order lifts psychedelics biotechs

Meant to speed research and access to psychedelics for mental health conditions, the order is the latest in a series of developments that, to Wall Street, make psychedelics a more “investable space.”

By Jacob Bell • April 21, 2026

UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B

The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy in early testing for a hard-to-treat form of a common epilepsy.

By Jacob Bell • April 17, 2026

Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool

Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell engager.

By Ben Fidler • April 17, 2026

Kailera nets $625M in one of biotech’s biggest-ever IPOs

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to support a portfolio of medicines licensed from China’s Hengrui Pharma.

By Gwendolyn Wu • April 16, 2026

Replimune cuts staff; MeiraGTx reacquires eye gene therapy

Replimune is laying off 63 staffers days after the second FDA rejection of its melanoma drug. Elsewhere, Revolution raised $2 billion and a regulatory filing revealed details on negotiations between Biogen and Apellis.

By BioPharma Dive staff • April 16, 2026

Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.

By Delilah Alvarado • April 15, 2026

Terremoto raises $108M to pursue development of drugs targeting AKT

The California biotech has one therapy in Phase 1 testing and expects another to advance to the clinic later this year.

By Kristin Jensen • April 15, 2026

Travere wins long-awaited approval for kidney disease drug

The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity believed to be worth more than $1 billion annually. 

By Delilah Alvarado • April 14, 2026

Novo teams with OpenAI; Ideaya gets muted response to eye drug data

Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into radiopharmaceuticals and a GSK cancer drug showed early promise.

By BioPharma Dive staff • April 14, 2026

Spyre drug for inflammatory bowel disease shows promise in early study

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” profile, the company said. 

By Delilah Alvarado • April 13, 2026

Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy. 

By Gwendolyn Wu • April 13, 2026